Histone deacetylase inhibitors: targeting epigenetic regulation in the treatment of acute leukemia

• Published in: Therapeutic advances in hematology Vol. 15; p. 20406207241283277
• Main Authors: Xiao, Tong, Chen, Zhigang, Xie, Yutong, Yang, Chao, Wu, Junhong, Gao, Lei
• Format: Journal Article
• Language: English
• Published: England SAGE Publications 01.01.2024; SAGE Publishing
• Subjects: Review; acute leukemia; histone deacetylase inhibitors
• ISSN: 2040-6207; 2040-6215
• DOI: 10.1177/20406207241283277

Acute leukemia (AL) is a rare yet perilous malignancy. Currently, the primary treatment for AL involves combination chemotherapy as the cornerstone of comprehensive measures, alongside hematopoietic stem cell transplantation as a radical approach. However, despite these interventions, mortality rates remain high, particularly among refractory/recurrent patients or elderly individuals with a poor prognosis. Acetylation, a form of epigenetic regulation, has emerged as a promising therapeutic avenue for treating AL. Recent studies have highlighted the potential of acetylation regulation as a novel treatment pathway. Histone deacetylase inhibitors (HDACis) play a pivotal role in modulating the differentiation and development of tumor cells through diverse pathways, simultaneously impacting the maturation and function of lymphocytes. HDACis demonstrate promise in enhancing survival rates and achieving a complete response in both acute myeloid leukemia and acute T-lymphoblastic leukemia patients. This article provides a comprehensive review of the advancements in HDACi therapy for AL, shedding light on its potential implications for clinical practice.